Funding awarded
- Germline-somatic interactions as drivers and therapeutic targets in bladder cancer awarded by American Cancer Society Principal Investigator 2026 - 2030
- Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer awarded by National Cancer Institute Principal Investigator 2023 - 2028
- Modeling Imetelstat Response in Bladder Cancer Organoid and PDX Models awarded by Geron Corporation Principal Investigator 2025 - 2027
- Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer awarded by Bladder Cancer Advocacy Network, Inc. Principal Investigator 2025 - 2026
- Characterization of CDADC1, a Putative CTP Deaminase Co-deleted with RB1 in Bladder Cancer awarded by American Association for Cancer Research Principal Investigator 2025 - 2026
- Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies awarded by Bladder Cancer Advocacy Network, Inc. Principal Investigator 2024 - 2026
- missing activity Principal Investigator 2025 - 2025
- Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer awarded by Starr Cancer Consortium Principal Investigator 2023 - 2025
- Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancer Principal Investigator 2023 - 2025
- missing activity Principal Investigator 2021 - 2024
- missing activity Principal Investigator 2020 - 2024
- An urinary drug disposing approach for treatment of bladder Cancer awarded by National Cancer Institute Co-Investigator 2023 - 2028
- Clinical and Translational Science Center - UL1 awarded by National Center for Advancing Translational Sciences Co-Investigator 2022 - 2027
- Clinical and Translational Science Center - UL1 awarded by National Center for Advancing Translational Sciences Co-Principal Investigator 2022 - 2027
- Targeting ecDNA to reverse therapy-resistance in urothelial cancer. awarded by United States Department of Defense Key Personnel 2024 - 2027
- Optimization Of Urinary DNA Deep Sequencing Tests To Enhance Clinical Staging Of Bladder Cancer Patients awarded by National Cancer Institute Principal Investigator Subaward 2021 - 2026